首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines
【24h】

Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines

机译:含三苯基鏻咪唑鎓盐的合成,表征和生物活性,抵御选择膀胱癌细胞系

获取原文
获取原文并翻译 | 示例
           

摘要

Imidazolium salts have shown great promise as anticancer materials. A new imidazolium salt (TPP1), with a triphenylphosphonium substituent, has been synthesized and evaluated for in vitro and in vivo cytotoxicity against bladder cancer. TPP1 was determined to have a GI(50) ranging from 200 to 250 mu M over a period of 1 h and the ability to effectively inhibit bladder cancer. TPP1 induces apoptosis, and it appears to act as a direct mitochondrial toxin. TPP1 was applied intravesically to a bladder cancer mouse model based on the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). Cancer selectivity of TPP1 was demonstrated, as BBN-induced tumors exhibited apoptosis but normal adjacent urothelium did not. These results suggest that TPP1 may be a promising intravesical agent for the treatment of bladder cancer. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:Imidazolium Salts已经表现出很有希望作为抗癌材料。 已经合成并评估了具有三苯基膦酰基取代基的新咪唑盐(TPP1),并在体外和体内细胞毒性下进行膀胱癌。 在1小时的时间内测定TPP1的GI(50),从200至250μm,有效抑制膀胱癌的能力。 TPP1诱导细胞凋亡,它似乎充当直接线粒体毒素。 基于致癌基因酰基 - 丁基-N-(4-羟基丁基)亚硝胺(BBN),TPP1以膀胱癌小鼠模型进行膀胱癌小鼠模型。 作为BBN诱导的肿瘤表现出细胞凋亡但正常相邻的尿液尿液没有,表现了TPP1的癌症选择性。 这些结果表明TPP1可能是治疗膀胱癌的有前途的膀胱内剂。 (c)2019年Elsevier Masson SAS。 版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号